Biotech Values

[DewDiligence]

XOMA—what makes you think that if [EYEGUARD A/C] are less severe forms of uveitis?

I’m saying we simply don’t know which of the three EYEGUARD studies has the best chance of succeeding. Some drugs show their efficacy more readily in mild disease, and some drugs show their efficacy more readily in advanced disease. It’s hard to say a priori which kind of drug Gevokizumab will be.